Pelosi plan to lower drug prices faces political challenges

Amy Baxter | | Health Exec | Policy & Regulations

House Speaker Nancy Pelosi’s (D-CA) bill to lower drug prices is facing new challenges as congressional Democrats debate changes to the plan, The Hill reported.

Centrist Democrats are warning leadership that if the plan moves further to the left, it could start to lose support and votes. Others are pushing for stronger reforms to “toughen up” the legislation.

“Pelosi will have to thread the needle between these dueling factions as she plans to bring the measure to the floor as soon as mid-November,” the report reads.

Pelosi introduced the plan in September, calling the bill The Lower Drug Costs Now Act. The plan enables the HHS to negotiate lower prices for hundreds of Medicare drugs––something currently prohibited under law.

See the full story below:

House Democrats clash over Pelosi's drug pricing bill

Amy Baxter
Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Related Content

Mangione now faces federal charges, death penalty in murder of UHC CEO
FDA issues Class I recall on counterfeit infusion pump batteries
FDA issues alert on PCNL sheath safety after patient death
DOJ sues CVS over unlawful opioid prescriptions and reimbursement
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders
Advancing AI for vascular surgery will require a commitment to data integrity

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.